Did Amy Schumer confirm she used Mounjaro?

Yes. Schumer publicly stated in 2023, through Instagram posts and podcast interviews, that she tried Mounjaro (tirzepatide) for postpartum weight management and later discontinued it due to side effects.

Why did Amy Schumer stop taking Mounjaro?

Schumer described intolerable gastrointestinal side effects. This aligns with clinical trial data showing that 5-10% of tirzepatide users discontinue due to adverse events, primarily nausea, vomiting, and diarrhea.

How common is it to quit GLP-1 medications because of side effects?

In phase 3 trials, discontinuation due to adverse events ranges from about 4% to 10% depending on the drug, dose, and population studied. Gastrointestinal symptoms are the primary driver. Real-world discontinuation rates may be higher, as clinical trial participants tend to be more closely monitored and supported than typical patients.

Has Oprah confirmed using a GLP-1 medication?

Yes. Oprah Winfrey publicly confirmed in late 2023 that she uses a GLP-1 receptor agonist as part of her weight management program. She has described it as one tool among several, including diet and exercise.

Is Mounjaro the same as Ozempic?

No. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1-only receptor agonist. Both reduce appetite and promote weight loss, but they work through partially different receptor mechanisms.

Amy Schumer Compared to Other Public GLP-1 Figures

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Amy Schumer Compared to Other Public GLP-1 Figures Image: HealthRX.com clinical image

At a glance

Celebrity: Amy Schumer
Drug: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
Status: Confirmed use, confirmed discontinuation
Reason for stopping: Self-reported intolerable side effects (primarily gastrointestinal)
Public disclosure: Instagram posts and podcast interviews, 2023
Clinical relevance: Reflects the ~6-10% discontinuation-due-to-adverse-events rate seen in tirzepatide phase 3 trials

Amy Schumer's GLP-1 Timeline

In 2023, Amy Schumer publicly stated that she had tried Mounjaro for postpartum weight management. She discussed her experience on Instagram and in podcast appearances, describing gastrointestinal side effects that she found too severe to continue the medication. This was not a quiet exit. Schumer was direct about what happened: the drug worked on appetite, but the nausea, vomiting, and related GI distress were not worth it for her.

What makes Schumer's disclosure unusual is its completeness. She named the drug. She described why she started it (postpartum weight). She explained why she stopped (side effects). And she did all of this voluntarily, without being caught or confronted. That sequence, confirmation of both initiation and discontinuation with a stated reason, is rare in celebrity GLP-1 stories.

The Celebrity GLP-1 Disclosure Spectrum

To understand where Schumer fits, it helps to map the broader pattern of how public figures have discussed GLP-1 medications. These disclosures fall into roughly four categories.

Confirmed and ongoing. Some celebrities have publicly confirmed using a GLP-1 agonist and appear to remain on therapy. Oprah Winfrey confirmed in late 2023 that she uses a GLP-1 medication as part of her weight management, describing it as a tool alongside diet and exercise. Sharon Osbourne confirmed semaglutide use and discussed significant weight loss, though she later expressed concern about losing too much weight.

Confirmed and discontinued. This is where Schumer sits. She confirmed use, then confirmed stopping. This category is small, and Schumer's case stands out because her reason for discontinuation (side effects) aligns with published adverse event rates in clinical trials.

Publicly speculated but not confirmed. A much larger group of celebrities have been the subject of public speculation about GLP-1 use based on visible weight changes, but have not confirmed or denied use. The HealthRX.com Medical Team does not treat speculation as evidence, and attributing medication use to anyone who has not confirmed it publicly would be irresponsible.

Denied. A few public figures have actively denied using GLP-1 medications when asked. These denials exist in the public record but cannot be independently verified.

What the Clinical Data Says About Discontinuation

Schumer's experience, wanting the metabolic benefit but finding the gastrointestinal burden intolerable, is not an outlier. It is a well-documented outcome in tirzepatide registration trials.

In the SURMOUNT-1 trial, which evaluated tirzepatide for obesity, discontinuation rates due to adverse events ranged from 4.3% to 7.1% across the 5 mg, 10 mg, and 15 mg dose groups, compared to 2.6% for placebo. The most common reasons were gastrointestinal: nausea (up to 33.3%), diarrhea (up to 23.0%), vomiting (up to 12.2%), and constipation (up to 11.6%). Most GI events were mild to moderate and occurred during dose escalation, but a meaningful subset of patients found them severe enough to quit.

For semaglutide, the STEP trial program showed a similar pattern. In STEP-1, 7.0% of participants on semaglutide 2.4 mg discontinued due to adverse events versus 3.1% on placebo. GI symptoms again dominated the adverse-event profile.

The HealthRX.com Medical Team notes that these discontinuation rates, while reported as single-digit percentages, translate to a large absolute number of people when millions of prescriptions are written. Per FDA postmarketing data, GI complaints remain the most frequently reported adverse events for GLP-1 receptor agonists in real-world use.

Disclosure Patterns and What They Reveal

The way celebrities talk about GLP-1 medications shapes public perception of these drugs in ways that clinical trial summaries do not. Three patterns stand out.

Side effects are underrepresented in celebrity narratives. Most public GLP-1 stories focus on weight loss results. Schumer's story is one of the few that centers tolerability. This creates a skewed picture for the public: the success stories are amplified while the quit stories are rare. Clinical data tells a different story, where up to one in ten patients on higher GLP-1 doses may discontinue due to adverse events.

Confirmation bias in public speculation. When a celebrity loses weight and does not disclose medication use, public speculation often fills the gap. This is not informative. Weight changes have many causes, and attributing them to a specific drug without confirmation is guesswork. The HealthRX.com Medical Team treats only confirmed, on-the-record statements as usable data points.

Timing tracks with cultural moments, not clinical ones. Celebrity GLP-1 disclosures clustered in 2023 and 2024, coinciding with peak media coverage of semaglutide and tirzepatide shortages. Disclosure is driven by cultural pressure, not by the pharmacology itself.

Mounjaro vs. Other GLP-1 Agents: Why the Drug Matters

Schumer specified that she used Mounjaro (tirzepatide), not Ozempic or Wegovy (semaglutide). This distinction matters clinically.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide activates only the GLP-1 receptor. In head-to-head data from the SURPASS trials, tirzepatide produced greater A1C reductions and weight loss compared to semaglutide 1 mg in type 2 diabetes populations. The GI side-effect profiles are broadly similar between the two drug classes, though direct comparative tolerability data in obesity populations remains limited.

For a patient like Schumer who found tirzepatide's side effects intolerable, a common clinical question is whether switching to semaglutide (or vice versa) might be better tolerated. The American Gastroenterological Association has noted that individual GI tolerability varies, and switching within the GLP-1 class is a reasonable clinical strategy. Slower dose titration, dietary modifications (smaller meals, avoiding high-fat foods), and temporary use of antiemetics can also improve tolerability.

The HealthRX.com Medical Team Take

Amy Schumer's GLP-1 story is clinically valuable precisely because it did not end with a dramatic before-and-after photo. She tried the drug, found the side effects unacceptable, and stopped. That outcome, while less exciting than a 50-pound transformation, is statistically common and medically important.

The celebrity GLP-1 conversation disproportionately features success stories. This creates a gap between public expectation and clinical reality. Patients starting GLP-1 therapy should understand that gastrointestinal side effects occur in 40-70% of users across clinical trial populations, that most are mild to moderate and improve over time, but that a real subset of patients will not tolerate them at any dose.

Schumer's willingness to describe both the attempt and the failure gives the public a data point that clinical trial tables contain but Instagram rarely shows. That is where the value lies: not in celebrity endorsement or rejection of GLP-1 drugs, but in honest accounts of variable individual response that match what prescribers see in practice every day.

Frequently asked questions

›

References

Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. pubmed.ncbi.nlm.nih.gov/35658024
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. pubmed.ncbi.nlm.nih.gov/33567185
Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. pubmed.ncbi.nlm.nih.gov/34170647
Rubino DM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2023;329(14):1414-1425. pubmed.ncbi.nlm.nih.gov/36726222
FDA. Medications containing semaglutide marketed for type 2 diabetes or obesity. fda.gov
AGA Clinical Practice Update on Management of GI Side Effects of GLP-1 Receptor Agonists. pubmed.ncbi.nlm.nih.gov/37995689